Search Clinical Trials

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

The main questions it aims to answer are:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• To evaluate preliminary efficacy to the drug
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

Participants will:

• Provide written informed consent
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, based on how well a participant is doing on treatment
• Be followed for progression every 3 months for up to 2 years

本研究的主要目的是评估E7386的安全性和耐受性，并确定E7386与其他抗癌药物联合的推荐2期剂量(RP2D)。.

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, prostate cancer, and "All-Tumors").

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, 生长抑素受体表达(SSTR+)的胃肠胰神经内分泌肿瘤(GEP-NETs)在接受Lutetium 177标记的生长抑素类似物(177Lu-SSA)治疗后进展, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), 在490例复发/进展的晚期癌症患者中，AZD9574单独和联合抗癌药物的初步疗效.

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.

这是一项1期研究，旨在评估ARX517在转移性去势抵抗性前列腺癌(mCRPC)成人患者中的安全性和耐受性。.

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

RSC-101是RSC-1255在成人研究参与者中进行的一项1a/1b期临床试验，这些参与者患有晚期实体肿瘤恶性肿瘤，对现有已知的临床益处治疗不耐受, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. 1a期(剂量递增)的目的是确定适当的治疗剂量，1b期(剂量扩展)的目的是表征RSC-1255的安全性和有效性.

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

该II期试验研究abemaciclib在治疗具有CDK4/6通路激活且复发(复发)的卵巢癌或子宫内膜癌患者方面的效果如何. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.

本探索性研究探讨了一种名为68Ga-FAPi-46 PET/CT的成像技术如何确定FAPI示踪剂(68Ga-FAPi-46)在癌症患者的正常和癌组织中积聚的位置和程度. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.

Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

第一阶段将评估不同剂量水平的repotrectinib在患有晚期或转移性淋巴瘤激酶(ALK)的儿童和年轻成人患者中的安全性和耐受性。, receptor tyrosine kinase encoded by the gene ROS1 (ROS1), 或神经营养受体激酶基因编码TRK激酶家族(NTRK1-3)的改变来估计最大耐受剂量(MTD)或最大给药剂量(MAD)并选择儿科推荐的2期剂量(RP2D)。.

二期试验将确定repotrectinib在ROS1或NTRK1-3改变的晚期或转移性恶性肿瘤的儿童和青年患者中的抗肿瘤活性.

在这项观察性研究中，研究人员希望更多地了解药物VITRAKVI(通用名称:larorectinib)的有效性，以及该药物在TRK融合癌患者常规使用期间的耐受性如何，这些患者局部进展或从其开始的地方扩散到身体的其他部位. TRK融合癌是一个术语，用于描述由NTRK(神经营养酪氨酸激酶)基因的变化引起的各种常见和罕见的癌症，称为融合. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. 该研究将招募患有NTRK基因融合实体瘤的成人和儿童患者，他们的治疗医生已经决定用VITRAKVI治疗他们的疾病. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.